NEWS AND PRESS
PRESS RELEASE: Reapplix wins EY Entrepreneur Of The Year award in the Life Science category
As the Reapplix team proudly received the prestigious EY Entrepreneur Of The Year award in the Life Sciences category at the annual gala event in Copenhagen, Denmark on November 29, 2018, the jury emphasised the big market potential and innovative approach to wound healing deployed by Reapplix:
3C PATCH® WILL BE THE NEW NAME FOR LEUCOPATCH® IN 2019
Based on the positive clinical results documented in the outcome data (recently published in The Lancet Diabetes & Endocrinology) of a major international randomized controlled trial of our LeucoPatch® wound healing technology, Reapplix’s primary focus now shifts from development to commercialization.
PRESS RELEASE: New help on the way for people with diabetic foot ulcers
A major international randomized controlled trial (RCT) has just been published in the internationally recognized journal The Lancet Diabetes & Endocrinology and documents the effect of a new treatment, LeucoPatch®, which offers significant enhancement of healing of hard-to-heal foot ulcers.
PRESS RELEASE: Positive outcome data of large Randomized Controlled Trial presented at American Diabetes Association Scientific Sessions & Reapplix business update
Reapplix ApS, the regenerative medicine company, initially focussed on chronic wounds, announces that positive outcome data of an independent Randomized Controlled Trial (RCT) of its LeucoPatch® wound healing platform was presented at the American Diabetes Association 78th Scientific Sessions meeting in Orlando, Florida. The Company has also provided an update on the Company’s progress.
Dr. Magnus Löndahl presented Clinical experiences with LeucoPatch and the status of the large RCT at the Innovations in Wound Healing meeting.
MD, PhD Magnus Löndahl one of 4 principal investigators of the large randomized controlled trial of LeucoPatch/3C Patch on diabetic foot ulcers presented “Clinical experiences with LeucoPatch and status of the large RCT: Leucopatch™ System in the Management of Hard-To-Heal Diabetic Foot Ulcers” at the 4th annual Innovations in Wound Healing meeting December 9th 2017 in Bimini, Bahamas.
Reapplix scientific team presented data at The Diabetic Lower Extremity Symposium
Data were presented in a poster format and was titled: “3C Patch derived autologous immune cells delivers immune responses appropriate for the treatment of Diabetic Foot Ulcers”
Reapplix presents poster at Diabetic Foot Study Group meeting in Porto
The Reapplix team have the pleasure to participate at the 14TH ANNUAL MEETING OF THE DFSG, 8-10 September 2017.
PRESS RELEASE: Reapplix announces new US FDA 510(k) clearance for expanded system, including automated centrifuge, a further advancement of its regenerative wound care technology
Reapplix today announced that it has received US FDA 510(k) clearance for its 3C Patch System® including the 3C Patch Centrifuge, currently being used at selected centres across Europe to treat a variety of hard to heal wounds.
PRESS RELEASE: New clinical trial to evaluate LeucoPatch® in the treatment of malleoli ulcers
Reapplix today announced that it is funding a new clinical study for LeucoPatch®, on the healing of ulcers on the malleoli, a bony prominence on the ankle, which are often very hard-to-heal, due to the thin layer of tissue over this area.
PRESS RELEASE: Reapplix confirms new funds raised
Reapplix today announced that it has successfully closed a new funding round of €2.7 million. This new funding was provided by the existing investors, SEED Capital Denmark, Novo Seeds and Vækstfonden (The Danish Growth Fund).
Patent news – Patents granted in China and Canada
Reapplix ApS, developers of the unique LeucoPatch active wound therapy, have today announced that they have received notification of key patent grants in China and Canada.
Study Shows Effectiveness of LeucoPatch in Healing Diabetic Foot Ulcers
A newly published study using LeucoPatch, a unique active wound therapy, developed by Reapplix ApS (Reapplix), has been published showing that LeucoPatch was highly effective in healing diabetic foot ulcers.
Reapplix Patents Granted in USA and Japan
Reapplix ApS, developers of the unique LeucoPatch active wound therapy, have today announced that they have received notification that key patents have been granted in the United States and in Japan.
REAPPLIX ANNOUNCED AS INNOVATION PRIZE WINNER 2014 IN ‘THE ENGINEER’
Reapplix was today announced as the winner of ‘The Engineer’ Product Prize 2014 in the Innovation category.
REAPPLIX – 2014 EY ENTREPRENEUR OF THE YEAR FINALIST
Reapplix was chosen from the selected participants in the 2014 EY Entrepreneur Of The Year in Denmark as a top 3 finalist in the Life Sciences category.
LeucoPatch support the work of the diabetic foot study group
To support the important work done by the Diabetic Foot Study Group (DFSG), Reapplix – the company behind The LeucoPatch – is a Silver sponsor of the yearly DFSG meeting.
LeucoPatch featured in Danish television
“Lise Tarnow, TV2 Lorry”: www.tv2lorry.dk/arkiv/2014/7/14?video_id=93064
The large randomized clinical trial of LeucoPatch speeds up
Clinical sites are continuously being added to the LeucoPatch RCT Recently sites in Lincoln, Dudley and Sheffield have joined us – welcome!
Large international randomized controlled trial on LeucoPatch started 2013
A study of more than 250 diabetic foot ulcer patients will be initiated in cooperation with principal investigators Dr. Löndahl, Dr. Game, Prof. Jeffcoate and Dr. Tarnow at several multidisciplinary team based clinical sites in UK, Denmark and Sweden.
Scandinavian multicenter study of LeucoPatch presentented at EWMA 2013
Final clinical data from the LeucoPatch diabetic foot ulcer study were presented by Clinical investigator Dr. Bo Jørgensen at the European Wound Management Association meeting held in Copenhagen.
PRESS RELEASE: Reapplix announces new US FDA 510(k) clearance for expanded system, including automated centrifuge, a further advancement of its regenerative wound care technology
Reapplix today announced that it has received US FDA 510(k) clearance for its 3C Patch System® including the 3C Patch Centrifuge, currently being used at selected centres across Europe to treat a variety of hard to heal wounds.
PRESS RELEASE: New clinical trial to evaluate LeucoPatch® in the treatment of malleoli ulcers
Reapplix today announced that it is funding a new clinical study for LeucoPatch®, on the healing of ulcers on the malleoli, a bony prominence on the ankle, which are often very hard-to-heal, due to the thin layer of tissue over this area.
PRESS RELEASE: Reapplix confirms new funds raised
Reapplix today announced that it has successfully closed a new funding round of €2.7 million. This new funding was provided by the existing investors, SEED Capital Denmark, Novo Seeds and Vækstfonden (The Danish Growth Fund).
PRESS RELEASE: LeucoPatch® Trial to continue following Interim Analysis
Reapplix today announced that it has been informed by the Trial Steering Committee for the ongoing LeucoPatch® Randomized Controlled Trial (ClinicalTrials.gov NCT02224742) that a planned interim analysis has been performed.
PRESS RELEASE: Reapplix receives US FDA 510(k) clearance
Reapplix today announced that it has received US FDA 510(k) clearance for its 3C Patch System™. Reapplix’s proprietary simple-to-use device technology has been cleared for the following indications for use:
PRESS RELEASE: CMS approves Reapplix clinical study for reimbursement coverage
Reapplix ApS (Reapplix), developers of the unique LeucoPatch® active wound therapy, have today announced that the Centers for Medicare and Medicaid Services (CMS) in the USA have approved Reapplix’s clinical research study protocol for Coverage with Evidence Development.
PRESS RELEASE: Reapplix announces appointment of Graeme Brookes as new CEO
Reapplix ApS (Reapplix), developers of the unique LeucoPatch active wound therapy, have appointed Graeme Brookes as Chief Executive Officer. Graeme’s appointment significantly strengthens the commercial capabilities of the management team and provides increased emphasis on implementing this promising technology into clinical use.